影响中国汉族≥75岁老年口服华法林病人IWPC预测模型准确性的相关因素

doi:10.3969/j.issn.1003-9198.2021.02.005

摘要/Abstract

摘要： 目的探讨影响≥75岁老年病人国际华法林药物基因组协会(IWPC)预测模型准确性的相关因素,为≥75岁病人更合理地应用华法林提供参考。方法收集≥75岁口服华法林抗凝治疗的老年病人的临床资料,根据预测剂量与实际剂量间的差异率分为差异轻微组、差异一般组和差异显著组,比较各组性别、年龄、BMI、血压、心率、合并疾病及合并用药等临床指标差异,并分析各指标与剂量差异率的相关性。结果 73例病人分为差异轻微组42例,差异一般组21例,差异显著组10例。3组病人性别、年龄、肝功能等指标及各基因型分布差异无统计学意义(P>0.05)。差异轻微组心力衰竭(心衰)病史及应用利尿剂比例明显低于差异显著组,血清肌酐明显低于差异一般组及差异显著组,估算的肾小球率过滤(eGFR)明显高于差异一般组及差异显著组,差异有统计学意义(均P<0.05)。差异轻微组华法林实际剂量明显高于差异显著组(P<0.05)。有序多元Logistic回归分析显示,心衰病史及是否应用利尿剂对病人剂量差异率无显著影响(P>0.05)。将eGFR按四分位数分为低水平[(<59.5 mL/(min·1.73m²)]、中低水平[59.5~76.3 mL/(min·1.73m²)]、中高水平[76.4~96.5 mL/(min·1.73m²)]、高水平[>96.5 mL/(min·1.73m²)]4个等级,eGFR低水平病人引起华法林实际与预测剂量间明显差异的OR值是eGFR高水平病人的4.455倍;eGFR中低水平病人引起华法林实际与预测剂量间明显差异的OR值是eGFR高水平病人的5.135倍。结论中国汉族≥75岁病人华法林平均实际稳定剂量<2.5 mg/d;实际剂量越低,与IWPC模型公式预测剂量差异越大;eGFR与剂量差异大小有显著相关性。

关键词: 老年人, 华法林, IWPC预测模型, 稳定剂量

Abstract: Objective To explore the related factors that affect the accuracy of international warfarin phamacogenetics consortium (IWPC) prediction model in the patients aged ≥75 years old receiving warfarin, and to provide a reference for reasonable usage of warfarin. Methods The clinical data of the patients aged ≥75 years old receiving warfarin were collected. According to the difference rate between the predicted dose and the actual dose, the patients were divided into mild difference group (42 cases), moderate difference group (21 cases), significant difference group (10 cases). The clinical indicators of each group, including gender, age, body mass index, blood pressure, heart rate, comorbidities and concomitant medication were compared, and the influencing factors were analyzed. Results There were no significant differences in sex, age, liver function index and genotype distribution among the three groups (P>0. 05). The history of heart failure and the proportion of diuretics used in the mild difference group were significantly lower than those in the significant difference group, and the serum creatinine of mild difference group was significantly lower and the estimated glomerular filtration rate(eGFR) was significantly higher than that in the moderate difference group and the significant difference group (P<0. 05). History of heart failure and diuretics showed no significant effects on the dosage of warfarin (P>0. 05). According to the quartile, eGFR was divided into low level [<59. 5 mL/(min·1. 73m²)],middle-low level[59. 5~76. 3 mL/(min·1. 73m²)] , middle-high level [76. 4~96. 5 mL/(min·1. 73m²)] and high level[>96. 5 mL/(min·1. 73m²)] group. The difference between the actual and predicted dose of warfarin caused by the low level of eGFR was 4. 455 times of that of the high level of eGFR; The difference between the actual and predicted dose of warfarin caused by the middle-low level of eGFR was 5. 135 times higher than that of the high level of eGFR. Conclusions The average actual stable dose of warfarin in the patients aged≥75 years old of Han Chinese is less than 2. 5 mg/d, the lower of the actual dose, the greater of the difference with the predicted dose by IWPC model formula, and there is a significant correlation between eGFR and dose difference.

Key words: aged, warfarin, IWPC prediction model, stable dose

中图分类号:

R 973.2

杨海燕, 李曼, 潘丰慧, 崔雯霞, 施晓婷, 高蕾, 王春. 影响中国汉族≥75岁老年口服华法林病人IWPC预测模型准确性的相关因素[J]. 实用老年医学, 2021, 35(2): 126-131.

YANG Hai-yan, LI Man, PAN Feng-hui, CUI Wen-xia, SHI Xiao-ting, GAO Lei, WANG Chun. Relevant factors influencing the accuracy of IWPC prediction model in Chinese Han elderly patients with oral warfarin[J]. Practical Geriatrics, 2021, 35(2): 126-131.

参考文献

[1] INTERNATIONAL WARFARIN PHAMACOGENETICS CONSORTIUM. Estimation of the warfarin dose with clinical and phamacogenetics data[J]. N Engl J Med, 2009,360(8):753.
[2] 管文燕,徐航,叶庆,等.基因型指导我国汉族人群华法林稳定治疗剂量预测模型的验证及评价[J]. 中国药房,2016,11(27):1445-1450.
[3] 倪立,初亚男,张婕妤,等. CYP2C9;VKORC1基因多态性对华法林抗凝治疗维持剂量的影响[J]. 药学与临床研究,2014,12(22):492-494.
[4] 方素君,林玮玮,林荣芳,等. VKORC1-3673G>A、CYP2C9*3、CYP4F2 rs 2108622和CYP2C19*2基因多态性对中国汉族房颤患者华法林维持剂量的影响[J]. 中国现代应用药学,2018,9(35):1379-1383.
[5] PERERA M A,CAVALLARI L H,LIMDI N A,et al.Genetic variants associated with warfarin dose in African-American individuals:a genome-wide associated study[J]. Lancet,2013,382(9894):790-796.
[6] YIN T, MIYATA T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 rational and perspectives[J]. Thromb Res, 2007,120(1):1-10.
[7] CHEN J,SHAO L,GONG L,et al. A pharmacogenetics-based warfarin maintenance dosing algorithm from northern Chinese patients[J].PLoS One,2017,9(8):e105250.
[8] ZHANG W,WEN W,XUAN B,et et al.Effect of CYP2C9,CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients[J].Blood Coagul Fibrinolysis,2015,26(2):167-174.
[9] ZHONG S L,YU X Y,LIU Y,et al.Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients[J].Pharmacogenet Genomics,2012,22(3):176-182.
[10] YOU J H,WONG R S,WATY M M,et al. Warfarin dosing algorithm using clinical,demographic and pharmacogenetic data from Chinese patients[J].J Thromb Thrombolysis,2011,31(1):113-118.
[11] ZENG W T,ZHENG Q S,HUANG M,et al.Genetic polymorphisms of VKORC1,CYP2C9,CYP4F2 in Bai,Tibetan Chinese[J].Pharmazie,2012,67(1):67-73.
[12] RASMUSSEN M A,SKOV J,BLADBJERG E M,et al. Multivariate ananlysis of the relation between diet and warfarin dose[J].Eur J Clin Pharmacol,2012,68(3):321-328.
[13] Important information to know when you are taking:warfarin(coumadin) and vitamin K[DB/OL].e-pub ahead of print 5 September 2012;Http://www.cc.nih.gov/ccc/patient_education/drug_nutrient/coumadinl.pdf.
[14] FUSARO M, DALLE CARBONARE L, DUSSO A,et al. Differential effects of dabigatran and warfarin on bone volume and structure in rats with normal renal function[J]. PLoS One, 2015,10(8):e0133847.
[15] LIMDI N A, LIMDI M A,CAVALLARI L,et al.Warfarin dosing in patients with impaired kidney function[J]. Am J Kidney Dis,2010,56(5):823-831.
[16] JUN M, JAMES MT,MA Z,et al.Warfarin initiation,and kidney function: Comparative effectiveness and safety of warfarin in older adults with newly diagnosed atrial fibrillation[J]. Am J Kidney Dis,2017,69(6):734-743.
[17] CHANG C C, LIOU H H, WU C L,et al. Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation[J]. Clin Interv Aging,2013,8:523-529.